@biofinder.bsky.social
4️⃣ Finally, in a subsample we tested whether mass-spectrometry (MS) based methods would improve the results compared to immunoassays (IA). MS showed significantly higher accuracy and sensitivity, but PPV remained comparable to that of IA.
September 16, 2025 at 7:15 AM
4️⃣ Finally, in a subsample we tested whether mass-spectrometry (MS) based methods would improve the results compared to immunoassays (IA). MS showed significantly higher accuracy and sensitivity, but PPV remained comparable to that of IA.
3️⃣ In a hypothetical trial aiming to recruit 100 amyloid-positive individuals, there was >40% reduction in number of PET/CSF tests in blood-based approaches, although the initial number of individuals needed were increased.
September 16, 2025 at 7:15 AM
3️⃣ In a hypothetical trial aiming to recruit 100 amyloid-positive individuals, there was >40% reduction in number of PET/CSF tests in blood-based approaches, although the initial number of individuals needed were increased.
2️⃣ Next, we investigated a 2-step approach in which 🩸p-tau217 positive individuals were confirmed with CSF or PET.
With this approach, PPV increased to over 90% while maintaining sensitivity.
With this approach, PPV increased to over 90% while maintaining sensitivity.
September 16, 2025 at 7:15 AM
2️⃣ Next, we investigated a 2-step approach in which 🩸p-tau217 positive individuals were confirmed with CSF or PET.
With this approach, PPV increased to over 90% while maintaining sensitivity.
With this approach, PPV increased to over 90% while maintaining sensitivity.
1️⃣ In a sample of 2916 cognitively unimpaired individuals we found that plasma p-tau217🩸alone (single-step) was able to determine amyloid-b status with good accuracy and, most importantly, with a positive predictive value (PPV) around 80%.
September 16, 2025 at 7:15 AM
1️⃣ In a sample of 2916 cognitively unimpaired individuals we found that plasma p-tau217🩸alone (single-step) was able to determine amyloid-b status with good accuracy and, most importantly, with a positive predictive value (PPV) around 80%.
6/🧵 More asymmetric tau accumulation was tied to faster cognitive decline, particularly in regions affected at later disease stages.
September 5, 2025 at 2:39 PM
6/🧵 More asymmetric tau accumulation was tied to faster cognitive decline, particularly in regions affected at later disease stages.
5/🧵 Longitudinally, Aβ asymmetry at baseline predicted subsequent increase in tau asymmetry over time, especially in participants who hadn’t yet developed neocortical tau deposits. The affected Braak regions depended on disease stage and progression.
September 5, 2025 at 2:39 PM
5/🧵 Longitudinally, Aβ asymmetry at baseline predicted subsequent increase in tau asymmetry over time, especially in participants who hadn’t yet developed neocortical tau deposits. The affected Braak regions depended on disease stage and progression.
4/🧵 We replicated this Aβ-tau asymmetry link across three independent cohorts (OASIS-3, A4, ADNI), showing it is a consistent feature throughout the AD continuum.
September 5, 2025 at 2:39 PM
4/🧵 We replicated this Aβ-tau asymmetry link across three independent cohorts (OASIS-3, A4, ADNI), showing it is a consistent feature throughout the AD continuum.
3/🧵 There were no significant differences in inter-hemispheric connectivity (functional or structural) between asymmetric and symmetric tau groups. Instead, we observed a strong association between the laterality of Aβ and tau pathology, especially in temporal regions.
September 5, 2025 at 2:39 PM
3/🧵 There were no significant differences in inter-hemispheric connectivity (functional or structural) between asymmetric and symmetric tau groups. Instead, we observed a strong association between the laterality of Aβ and tau pathology, especially in temporal regions.
2/🧵 We assessed both inter-hemispheric brain connectivity (using RSfMRI and dMRI) and the spatial distribution of Aβ in 452 A+T+ participants from the Swedish BioFINDER-2 cohort to investigate the differences between asymmetric and symmetric tau pathology distribution.
September 5, 2025 at 2:39 PM
2/🧵 We assessed both inter-hemispheric brain connectivity (using RSfMRI and dMRI) and the spatial distribution of Aβ in 452 A+T+ participants from the Swedish BioFINDER-2 cohort to investigate the differences between asymmetric and symmetric tau pathology distribution.
1/🧵 In this study, we tried to disentangle whether tau asymmetry is due to reduction in inter-hemispheric brain connectivity (potentially restricting tau spread), or if it is linked to asymmetric amyloid-beta (Aβ) deposition (indicating greater hemisphere-specific vulnerability to AD pathology).
September 5, 2025 at 2:39 PM
1/🧵 In this study, we tried to disentangle whether tau asymmetry is due to reduction in inter-hemispheric brain connectivity (potentially restricting tau spread), or if it is linked to asymmetric amyloid-beta (Aβ) deposition (indicating greater hemisphere-specific vulnerability to AD pathology).
3️⃣Most importantly, we also showed significant differences in longitudinal rates of change of several AD biomarkers.
August 22, 2025 at 2:31 PM
3️⃣Most importantly, we also showed significant differences in longitudinal rates of change of several AD biomarkers.
2️⃣Based on the most sensitive of these markers, we developed a plasma-based staging system that showed good correlation with other AD biomarkers.
August 22, 2025 at 2:31 PM
2️⃣Based on the most sensitive of these markers, we developed a plasma-based staging system that showed good correlation with other AD biomarkers.
1️⃣In brief, we showed that different plasma tau biomarkers were differently associated with different clinical stages of the disease.
August 22, 2025 at 2:31 PM
1️⃣In brief, we showed that different plasma tau biomarkers were differently associated with different clinical stages of the disease.
4/🧵Importantly, this two-step approach worked well across multiple clinical scenarios, including individuals with clinical parkinsonism, those with an Alzheimer's-like presentation, and clinically unimpaired participants where it reduced the need of CSF testing by up to 80%.
August 6, 2025 at 8:49 AM
4/🧵Importantly, this two-step approach worked well across multiple clinical scenarios, including individuals with clinical parkinsonism, those with an Alzheimer's-like presentation, and clinically unimpaired participants where it reduced the need of CSF testing by up to 80%.
2/🧵We developed a two-step approach, in which individuals would first perform a smell-function test👃(step1️⃣), and only those at high risk of having brain LBP based on their performance (adjusted for age and sex) would proceed to CSF SAA testing🧪 (step2️⃣).
August 6, 2025 at 8:49 AM
2/🧵We developed a two-step approach, in which individuals would first perform a smell-function test👃(step1️⃣), and only those at high risk of having brain LBP based on their performance (adjusted for age and sex) would proceed to CSF SAA testing🧪 (step2️⃣).
6️⃣Do certain regions uniquely mediate a given tau-cognition association? - Yes, tau–immediate recall was mediated by several MTL regions, tau–recognition by hippocampus & tau–semantic fluency by inferior temporal gyrus.
August 5, 2025 at 2:16 PM
6️⃣Do certain regions uniquely mediate a given tau-cognition association? - Yes, tau–immediate recall was mediated by several MTL regions, tau–recognition by hippocampus & tau–semantic fluency by inferior temporal gyrus.
5️⃣Mediating effects differed for cognitive domains: MTL & neocortical thickness mediated tau-immediate & -delayed recall associations. MTL subregional thickness mediated tau-late recall & -recognition associations. Neocortical regions mediated tau-semantic fluency associations.
August 5, 2025 at 2:16 PM
5️⃣Mediating effects differed for cognitive domains: MTL & neocortical thickness mediated tau-immediate & -delayed recall associations. MTL subregional thickness mediated tau-late recall & -recognition associations. Neocortical regions mediated tau-semantic fluency associations.
4️⃣ Baseline p-tau217, as well as GFAP, NfL, or t-tau, were also individually associated with longitudinal changes in Aβ-PET, and tau-PET.
June 27, 2025 at 11:54 AM
4️⃣ Baseline p-tau217, as well as GFAP, NfL, or t-tau, were also individually associated with longitudinal changes in Aβ-PET, and tau-PET.
3️⃣ We found that baseline p-tau217, GFAP, NfL, or t-tau, were individually associated with longitudinal changes in DS-MSE and progression to dementia. In combined models, only baseline p-tau217 remained associated. Similar associations were shown for longitudinal p-tau217.
June 27, 2025 at 11:54 AM
3️⃣ We found that baseline p-tau217, GFAP, NfL, or t-tau, were individually associated with longitudinal changes in DS-MSE and progression to dementia. In combined models, only baseline p-tau217 remained associated. Similar associations were shown for longitudinal p-tau217.
5/🧵CSF levels of p-tau biomarkers were not increased in ALS compared with controls. All four CSF p-tau assays had high performance for differentiating AD from ALS (AUCs, 0.97-0.98).
May 5, 2025 at 12:31 PM
5/🧵CSF levels of p-tau biomarkers were not increased in ALS compared with controls. All four CSF p-tau assays had high performance for differentiating AD from ALS (AUCs, 0.97-0.98).
4/🧵In addition, plasma p-tau217 Lilly and p-tau181 Lilly discriminated AD from ALS with higher accuracy than p-tau217 ALZpath and p-tau181 UGOT (AUCs 0.89-0.91 vs 0.54-0.74, respectively).
May 5, 2025 at 12:31 PM
4/🧵In addition, plasma p-tau217 Lilly and p-tau181 Lilly discriminated AD from ALS with higher accuracy than p-tau217 ALZpath and p-tau181 UGOT (AUCs 0.89-0.91 vs 0.54-0.74, respectively).
3/🧵Increases in AD vs ALS were significantly larger for the LMW-specific plasma assays (p-tau217 Lilly: 148.6%; p-tau181 Lilly: 86.5%) than the respective non-LMW-specific assays (p-tau217 ALZpath: 69.9%; p-tau181 UGOT-3.7%).
May 5, 2025 at 12:31 PM
3/🧵Increases in AD vs ALS were significantly larger for the LMW-specific plasma assays (p-tau217 Lilly: 148.6%; p-tau181 Lilly: 86.5%) than the respective non-LMW-specific assays (p-tau217 ALZpath: 69.9%; p-tau181 UGOT-3.7%).
5/🧵Those who remained free of neocortical tau pathology throughout their follow-up showed an Aβ–tau asymmetry link only in early Braak regions, whereas the ones that did progress showed this link in intermediate and late Braak regions.
April 25, 2025 at 9:35 AM
5/🧵Those who remained free of neocortical tau pathology throughout their follow-up showed an Aβ–tau asymmetry link only in early Braak regions, whereas the ones that did progress showed this link in intermediate and late Braak regions.
4/🧵Longitudinally, baseline Aβ asymmetry predicted the progression of tau asymmetry over time. This effect was most pronounced in early and intermediate Braak regions and in individuals who had not yet developed neocortical tau pathology.
April 25, 2025 at 9:35 AM
4/🧵Longitudinally, baseline Aβ asymmetry predicted the progression of tau asymmetry over time. This effect was most pronounced in early and intermediate Braak regions and in individuals who had not yet developed neocortical tau pathology.
3/🧵There were no differences in inter-hemispheric functional or structural connectivity between asymmetric and symmetric groups. However, we found a strong association between the laterality of tau and Aβ pathology, especially in the temporal regions.
April 25, 2025 at 9:35 AM
3/🧵There were no differences in inter-hemispheric functional or structural connectivity between asymmetric and symmetric groups. However, we found a strong association between the laterality of tau and Aβ pathology, especially in the temporal regions.